Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vion Pharmaceuticals has started an investigator-sponsored Phase I clinical trial of its lead anticancer agent Cloretazine in combination with hematopoietic cell transplant in patients with various advanced hematologic malignancies.
Subscribe to our email newsletter
The objective of the trial is to define the maximum tolerated dose of Cloretazine (VNP40101M) when given to patients of 18 to 65 years of age with poor-prognosis leukemia, lymphoma, and Hodgkin’s disease who are undergoing either an allogeneic or autologous HCT.
The trial is being conducted at The University of Texas M.D. Anderson Cancer Center.
Ann Cahill, vice president of clinical development at Vion, said: “We are hopeful that Cloretazine (VNP40101M) can make a contribution in the stem cell transplant setting.”